This in vivo study demonstrates that MEDI-573 inhibited the activity of IGF signaling pathways in mice implanted with two different tumor cell lines, C32 and P12. In this study, 86% and 91% tumor growth inhibition (TGI) was achieved in mice treated with 30 or 60 mg/kg MEDI-573, respectively.
In addition, the study found that using 18F-FDG-PET imaging (fluorodeoxyglucose positron emission tomography) may provide a non-invasive way to monitor treatment response within a few days of starting treatment, prior to documented reductions in the tumor size.
About MEDI-573 (Anti-IGF MAb)
IGF signaling pathways play an important role in the development and progression of many solid tumors. Disruption of IGF signaling pathways by neutralizing IGF-I and IGF-II ligands enables broader suppression of the IGF system and is a novel strategy for the treatment of solid tumors. MEDI-573 is a dual-targeting fully human monoclonal antibody that neutralizes IGF-I and IGF-II ligands. In preclinical studies, this neutralization was shown to block IGF-1R, IGF-1R/ IR-A hybrid and IR-A signaling, which inhibited cancer cell growth. MEDI-573 is in phase 1 clinical evaluation in patients with advanced solid tumors and is planned to begin phase 2 studies this year.
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.c
Copyright©2010 PR Newswire.
All rights reserved